DSGN
HealthcareDesign Therapeutics, Inc.
$8.69
$-0.41 (-4.51%)
Jan 5, 2026
Price History (1Y)
Analysis
Design Therapeutics, Inc. is a biotechnology company in the healthcare sector, with a market capitalization of $495.02 million and 55 employees. The company operates within the industry of biotechnology. The financial health of Design Therapeutics, Inc. reveals significant losses, with net income totaling -$67,446,000 (TTM). The company's margins are all zero percent, indicating no profitability. Returns on equity and assets also show negative values, at -29.8% and -20.5%, respectively. The balance sheet indicates a low level of debt ($1.74 million) and significant cash reserves ($205.97 million), resulting in a current ratio of 18.71. The valuation of Design Therapeutics, Inc. is characterized by a negative P/E ratio (TTM: -6.62) and forward P/E of -6.62. The price to book ratio stands at 2.48, while the EV/EBITDA ratio is -4.08. Dividend information is not available due to the company's lack of profitability.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Design Therapeutics, Inc.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Visit website →Key Statistics
- Market Cap
- $495.02M
- P/E Ratio
- N/A
- 52-Week High
- $10.31
- 52-Week Low
- $2.60
- Avg Volume
- 396.23K
- Beta
- 1.64
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 55